First Molecule Created to Suppress Major Component of Cancer Gene On-Off Switch
|
By LabMedica International staff writers Posted on 21 Oct 2010 |
In the endeavor to block the growth and spread of tumors, there have been many attempts to get cancer genes to ignore their internal regulatory instructions. In a new study, a team of scientists has created the first molecule able to prevent cancer genes from "hearing” those instructions, inhibiting the cancer process at its foundation.
The study, published online in late September 2010 by the journal Nature, demonstrated that proteins delivering stop and start instructions to a cancer gene--known as epigenetic "reader” proteins--can be targeted for future cancer therapies. The research is particularly pertinent to a rare but destructive cancer of children and young adults known as NUT midline carcinoma (NMC)--a disease so inflexible that no potential therapy for it has ever reached the stage of being evaluated in a clinical trial.
"In recent years, it has become clear that being able to control gene activity in cancer-- manipulating which genes are ‘on' or ‘off''--can be a high-impact approach to the disease,” said the study's senior author, James Bradner, M.D., of Dana-Farber Cancer Institute (Boston, MA, USA). "If you can switch off a cancer cell's growth genes, the cell will die. Alternatively, switching on a tissue gene can cause a cancer cell to become a more normal tissue cell.”
In this study, Dr. Bradner's lab synthesized a molecule that has both effects: by blocking a specific abnormal protein in NUT midline carcinoma cells, it stops them from dividing so prolifically and makes them ‘forget' they are cancer cells and start appearing more like normal cells. The assembled molecule affects the cell's multilayered machinery for controlling gene activity--the set of structures collectively known as the epigenome. Large portions of each gene play a regulatory role, dictating whether the gene is active, industriously sending orders for new proteins, or inactive, and temporarily at rest.
The gene's DNA is packaged in a substance called chromatin, which is the slate on which instructions to begin or cease activity are inscribed. The instructions themselves take the form of "bookmarks,” material placed on the chromatin by so-called epigenetic "writer” proteins. Another group of epigenetic proteins, known as "erasers,” is able to remove the bookmarks. Both types of proteins have effectively been disabled by researchers, using molecules generated in the laboratory or taken from nature. Their success has triggered intense interest in the development of anticancer therapies that work by blocking such proteins.
A third kind of epigenetic proteins--potentially the most appealing as therapeutic targets, because they switch genes on or off by "reading” the bookmarks--has received scant scientific attention. Dr. Bradner and his colleagues looked to this little-studied area of biology by focusing on NMC cells.
The disease is caused by a chromosomal translocation, in which two genes from different chromosomes become connected and give rise to an abnormal, fused protein known as BRD4-NUT. A review of the scientific literature suggested that some members of the benzodiazepine family of drugs, which includes Valium, Xanax, and Ativan, are active against "bromodomain” proteins such as BRD4. With that as a clue, Dr. Bradner and his Dana-Farber colleague Jun Qi, Ph.D., created an array of molecules to see if any inhibited a "reader” protein of the BRD4-NUT gene. One did, quite persuasively--a hybrid molecule, which researchers named JQ1, for Qi.
The investigators worked with researchers in the United States and overseas to learn more about the properties of JQ1 and how it works in cells. Stefan Knapp, Ph.D., of Oxford University (U.K.), provided crystal-clear images of the molecule bound to a protein; Olaf Wiest, Ph.D., of the University of Notre Dame (West Bend, IN, USA), showed that the molecule is less flexible in the presence of a protein, clarifying why it so effectively blocks the protein; and Andrew Kung, M.D., Ph.D., of Dana-Farber, modified animal models in which the molecule could be tested against NMC tumors.
The animal studies were especially promising. Investigators transplanted NMC cells from patients into laboratory mice, which were then given the JQ1 molecule. "The activity of the molecule was remarkable,” noted Dr. Bradner. "All the mice that received JQ1 lived; all that did not, died.”
For now, JQ1's primary utility is as a probe for better understanding the biology underlying NUT midline carcinoma. Drs. Bradner, Qi and their colleagues are customizing the molecule to maximize its effectiveness as a BRD4-NUT stopper. Ultimately, it, or a similar molecule, could be the basis for the first effective therapy against NMC.
"The disease tends to arise in the chest, head, or neck, along the vertical centerline of the body, with aggressive tumor growth and metastasis,” Dr. Bradner explained. "Patients may have a brief response to chemotherapy, but they eventually succumb to the spread of the disease.”
Unlike most cancers, NMC's tissue of origin is not known. It is a disease defined entirely by its genetic signature--the presence of the translocated gene BRD4-NUT. Prior to its genetic identification by Christopher French, M.D., of Brigham and Women's Hospital (Boston, MA, USA) and a study coauthor, NMC was not recognized as a definitive disease.
"This research further illustrates the promise of personalized medicine,” Dr. Bradner remarked, "which is the ability to deliver selected molecules to cancer-causing proteins to stop the cancer process while producing a minimum of residual side effects. The development of JQ1 or similar molecule into a drug may produce the first therapy specifically designed for patients with NMC.”
Related Links:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
The study, published online in late September 2010 by the journal Nature, demonstrated that proteins delivering stop and start instructions to a cancer gene--known as epigenetic "reader” proteins--can be targeted for future cancer therapies. The research is particularly pertinent to a rare but destructive cancer of children and young adults known as NUT midline carcinoma (NMC)--a disease so inflexible that no potential therapy for it has ever reached the stage of being evaluated in a clinical trial.
"In recent years, it has become clear that being able to control gene activity in cancer-- manipulating which genes are ‘on' or ‘off''--can be a high-impact approach to the disease,” said the study's senior author, James Bradner, M.D., of Dana-Farber Cancer Institute (Boston, MA, USA). "If you can switch off a cancer cell's growth genes, the cell will die. Alternatively, switching on a tissue gene can cause a cancer cell to become a more normal tissue cell.”
In this study, Dr. Bradner's lab synthesized a molecule that has both effects: by blocking a specific abnormal protein in NUT midline carcinoma cells, it stops them from dividing so prolifically and makes them ‘forget' they are cancer cells and start appearing more like normal cells. The assembled molecule affects the cell's multilayered machinery for controlling gene activity--the set of structures collectively known as the epigenome. Large portions of each gene play a regulatory role, dictating whether the gene is active, industriously sending orders for new proteins, or inactive, and temporarily at rest.
The gene's DNA is packaged in a substance called chromatin, which is the slate on which instructions to begin or cease activity are inscribed. The instructions themselves take the form of "bookmarks,” material placed on the chromatin by so-called epigenetic "writer” proteins. Another group of epigenetic proteins, known as "erasers,” is able to remove the bookmarks. Both types of proteins have effectively been disabled by researchers, using molecules generated in the laboratory or taken from nature. Their success has triggered intense interest in the development of anticancer therapies that work by blocking such proteins.
A third kind of epigenetic proteins--potentially the most appealing as therapeutic targets, because they switch genes on or off by "reading” the bookmarks--has received scant scientific attention. Dr. Bradner and his colleagues looked to this little-studied area of biology by focusing on NMC cells.
The disease is caused by a chromosomal translocation, in which two genes from different chromosomes become connected and give rise to an abnormal, fused protein known as BRD4-NUT. A review of the scientific literature suggested that some members of the benzodiazepine family of drugs, which includes Valium, Xanax, and Ativan, are active against "bromodomain” proteins such as BRD4. With that as a clue, Dr. Bradner and his Dana-Farber colleague Jun Qi, Ph.D., created an array of molecules to see if any inhibited a "reader” protein of the BRD4-NUT gene. One did, quite persuasively--a hybrid molecule, which researchers named JQ1, for Qi.
The investigators worked with researchers in the United States and overseas to learn more about the properties of JQ1 and how it works in cells. Stefan Knapp, Ph.D., of Oxford University (U.K.), provided crystal-clear images of the molecule bound to a protein; Olaf Wiest, Ph.D., of the University of Notre Dame (West Bend, IN, USA), showed that the molecule is less flexible in the presence of a protein, clarifying why it so effectively blocks the protein; and Andrew Kung, M.D., Ph.D., of Dana-Farber, modified animal models in which the molecule could be tested against NMC tumors.
The animal studies were especially promising. Investigators transplanted NMC cells from patients into laboratory mice, which were then given the JQ1 molecule. "The activity of the molecule was remarkable,” noted Dr. Bradner. "All the mice that received JQ1 lived; all that did not, died.”
For now, JQ1's primary utility is as a probe for better understanding the biology underlying NUT midline carcinoma. Drs. Bradner, Qi and their colleagues are customizing the molecule to maximize its effectiveness as a BRD4-NUT stopper. Ultimately, it, or a similar molecule, could be the basis for the first effective therapy against NMC.
"The disease tends to arise in the chest, head, or neck, along the vertical centerline of the body, with aggressive tumor growth and metastasis,” Dr. Bradner explained. "Patients may have a brief response to chemotherapy, but they eventually succumb to the spread of the disease.”
Unlike most cancers, NMC's tissue of origin is not known. It is a disease defined entirely by its genetic signature--the presence of the translocated gene BRD4-NUT. Prior to its genetic identification by Christopher French, M.D., of Brigham and Women's Hospital (Boston, MA, USA) and a study coauthor, NMC was not recognized as a definitive disease.
"This research further illustrates the promise of personalized medicine,” Dr. Bradner remarked, "which is the ability to deliver selected molecules to cancer-causing proteins to stop the cancer process while producing a minimum of residual side effects. The development of JQ1 or similar molecule into a drug may produce the first therapy specifically designed for patients with NMC.”
Related Links:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Latest BioResearch News
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
- Cancer DNA Trapping Mechanism Reveals Potential Target for Future Therapies
- Blood Antibody Signals May Offer Clues to the Origins of Childhood Cancer
Channels
Clinical Chemistry
view channel
Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine
Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Protein-Based Classifier Shows Promise for Predicting Melanoma Treatment Outcomes
Immune checkpoint inhibitors have improved melanoma treatment and extended survival over the past 15 years. However, many patients do not respond, and reliable biomarkers for predicting treatment response... Read more
Liquid Biopsy Gains FDA Approval to Guide Breast Cancer Combination Therapy
Estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer accounts for approximately 70% of cases. Acquired ESR1 mutations can cause resistance to endocrine... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







